| abstract |
The present invention particularly provides methods and compositions for treating complement-mediated diseases. In some embodiments, a recombinant human C1 esterase inhibitor protein having a half-life similar to or longer than a natural plasma-derived human C1 esterase inhibitor and methods of making the same are provided. In some embodiments, the present invention administers an effective amount of a recombinant human C1 esterase inhibitor protein to an individual suffering from or susceptible to a complement-mediated disease, such that the complement-mediated Methods are provided wherein at least one symptom or characteristic of a disease is prevented and / or reduced in intensity, severity, or frequency. [Selection] Figure 1 |